The Feminist Majority Foundation—they were heroic. They collected over 700,000 petitions from people across the United States ...

CAMBRIDGE, Mass., February 06, 2025--2seventy bio, Inc. (Nasdaq: TSVT) today provided full-year Abecma® (idecabtagene ...

Autolus Therapeutics' obe-cel, branded Aucatzyl, is the first CAR-T therapy approved without a REMS, highlighting its safety and unique mechanism.

Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

Cytokinetics , Inc. (NASDAQ:CYTK), with a market capitalization of $5.65 billion, is approaching a pivotal moment in its journey to become a leading player in the cardiovascular therapeutics market.

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

In the first 22 months of a mavacamten REMS program, few patients needed a temporary interruption in treatment for LVEF below 50%.

Heart failure may cause symptoms such as: Due to the risk of heart failure, Camzyos is available through a risk evaluation and mitigation strategies (REMS) program only. The FDA requires REMS ...